Impact of FGFR3 Alterations on First-Line Platinum Based Chemotherapy in Patients With Metastatic or Locally Advanced Urothelial Carcinoma: The Retrospective IFUCA Study
Clinical Genitourinary Cancer · 2026-02 · 24 (1) · 102465
DOI: 10.1016/j.clgc.2025.102465 ↗Kurz gefasst
Multizentrische Studie in der Zeitschrift Clinical Genitourinary Cancer, 2026-02. Verfasst von Thibaut Reverdy und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Centre Hospitalier Lyon Sud, Institut de cancérologie des Hospices Civils de Lyon, Lyon, France; Research on Healthca…. Hauptthemen laut MEDLINE: Receptor, Fibroblast Growth Factor, Type 3, Carcinoma, Transitional Cell, Antineoplastic Combined Chemotherapy Protocols, Urinary Bladder Neoplasms. Die Arbeit nennt 31 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Themen: Onkologische Pflege
Abstract (Originalsprache)
INTRODUCTION: FGFR3 alterations are observed in 10% to 15% of patients with advanced urothelial carcinoma (UC). We aimed to clarify the prognostic and predictive value of FGFR3 alterations in patients receiving first-line platinum-based chemotherapy (PBC) for advanced urothelial carcinoma. PATIENTS AND METHODS: We conducted a multicenter retrospective cohort study including patients with histologically confirmed UC treated in first line with PBC, with or without immune-checkpoint inhibitors (ICIs) administered as maintenance or second line. Only patients with known FGFR3 status on baseline tumor tissue, locally assessed were included. Progression-free survival (PFS) was the primary endpoint. Secondary endpoints included overall survival (OS), objective response rates (ORR), and PFS with ICIs, stratified by FGFR3 status. RESULTS: Between 2016 and 2022, 191 pts were included, of whom 58 (30.4%) had FGFR3-altered tumors (FGFR3^alt). Baseline characteristics were well balanced. ICIs were administered to 34% of patients. After a median follow-up of 32 months, median PFS under PBC was 6.6 months in FGFR3^alt and 7.5 in FGFR3 wild type subgroups (HR = 1.27; P = .15) respectively. Median OS was 22.1 versus 20.8 months (HR = 0.91; P = .658), and ORR in 133 pts were similar across subgroups (70.7% vs. 69.2% respectively). In multivariate analysis, FGFR3 status was not associated with survival. CONCLUSIONS: FGFR3 status did not significantly impact response to PBC in first-line treatment or ICIs. These findings underscore that the presence of an FGFR3 alteration does not guide the choice of platinum-based treatment, and the need for prospective biomarker-driven trials to identify best treatment sequences in advanced UC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Medical Oncology, Centre Hospitalier Lyon Sud, Institut de cancérologie des Hospices Civils de Lyon, Lyon, France; Research on Healthcare Performance RESHAPE, INSERM U1290, Université Claude Bernard Lyon 1…
- Department of Medical Oncology, Centre Léon Bérard, Lyon, France.
- Department of Medical Physics, centre Léon-Bérard, Université de Lyon, Insa Lyon, université Claude-Bernard Lyon 1, CNRS, U1294, Inserm, Creatis UMR 5220, Lyon, France.
- Department of Medical Oncology, Institut Bergonié, Bordeaux, France.
- Department of Medical Oncology, Hôpital Européen Georges Pompidou, Institut du Cancer Paris CARPEM, AP-HP Centre, Université de Paris Cité, Paris, France.
- Department of Medical Oncology, Hôpital Européen Georges Pompidou, Paris,France.
Zitieren
APA
Reverdy, T., Izarn, F., Allignet, B., Roubaud, G., Gibson, N., Teyssonneau, D., Thibault, C., Berthou, H., Houede, N., Fléchon, A., Tartas, S., Moinard-Butot, F., Barthelemy, P., & Maillet, D. (2026). Impact of FGFR3 Alterations on First-Line Platinum Based Chemotherapy in Patients With Metastatic or Locally Advanced Urothelial Carcinoma: The Retrospective IFUCA Study. Clinical Genitourinary Cancer, 24(1), 102465. https://doi.org/10.1016/j.clgc.2025.102465
Vancouver
Reverdy T, Izarn F, Allignet B, Roubaud G, Gibson N, Teyssonneau D, et al. Impact of FGFR3 Alterations on First-Line Platinum Based Chemotherapy in Patients With Metastatic or Locally Advanced Urothelial Carcinoma: The Retrospective IFUCA Study. Clinical Genitourinary Cancer. 2026;24(1):102465. doi:10.1016/j.clgc.2025.102465
BibTeX
@article{Reverdy2026,
author = {Reverdy, Thibaut and Izarn, Floriane and Allignet, Benoit and Roubaud, Guilhem and Gibson, Nyere and Teyssonneau, Diego and Thibault, Constance and Berthou, Hugo and Houede, Nadine and Fléchon, Aude and Tartas, Sophie and Moinard-Butot, Fabien and Barthelemy, Philippe and Maillet, Denis},
title = {Impact of FGFR3 Alterations on First-Line Platinum Based Chemotherapy in Patients With Metastatic or Locally Advanced Urothelial Carcinoma: The Retrospective IFUCA Study},
journal = {Clinical Genitourinary Cancer},
year = {2026},
volume = {24},
number = {1},
pages = {102465},
doi = {10.1016/j.clgc.2025.102465}
}
EUVIMED